Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions

Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions

Seeking Alpha • Feb 20, 2026

Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript

Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 20, 2026

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights For the three-month period ended December 31, 2025, as compared to the same period of 2024: Reported total revenue of $281.3 million, an increase of 39%, driven by: Oncology revenue of $189.9 million, an increase of 30%, and approximately 79,000 oncology tests.

Business Wire • Feb 19, 2026

Compared to Estimates, Guardant Health (GH) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Feb 20, 2026

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

Guardant Health (GH) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.62 per share a year ago.

Zacks Investment Research • Feb 20, 2026

Analyzing Profit Zones For Walmart, Quanta Services And Guardant Health Ahead Of Earnings | IBD

IBD's Alexis Garcia and Ed Carson preview key upcoming earnings reports from Walmart, Guardant Health and Quanta Services. Check out our daily newsletter!

Investors Business Daily • Feb 13, 2026

Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 12, 2026

Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open

Patient and Public Health Groups Invited to Apply for Up to 100 Shield Colorectal Cancer Blood Tests to Support Community Screening Events and Educational Outreach in March PALO ALTO, Calif., Feb. 12, 2026 /PRNewswire/ -- Ahead of Colorectal Cancer (CRC) Awareness Month in March, Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of its Community Colorectal Cancer Screening Grant Program, designed to support community-led efforts to expand access to colorectal cancer screening throughout March.

PRNewsWire • Feb 12, 2026

Guardant Health to Participate in Upcoming Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 10th TD Cowen 46th Annual Health Care Conference in Boston, MA Fireside chat on Wednesday, March 4th at 9:50 a.m. Eastern Time Leerink Partners Global He.

Business Wire • Feb 3, 2026

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

PALO ALTO, Calif. & ROCHESTER, Minn.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and before adjuvant chemotherapy. Results of the study, published in the Journal of Clinical Oncology.

Business Wire • Feb 2, 2026